Targeted Therapy Market is expected to reach US$ 147.16 billion by 2033 | Top key players - F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc.

Market Size and Growth:

The Targeted Therapy Market reached US$ 79.18 billion in 2024 and is expected to reach US$ 147.16 billion by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033.

Targeted Therapy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/targeted-therapy-market?sz

The Targeted Therapy Market refers to the healthcare sector focused on treatments that specifically target molecular and cellular mechanisms driving diseases, particularly cancer. Unlike traditional therapies, targeted therapies block the growth and spread of cancer by interfering with specific molecules. This market includes monoclonal antibodies, small molecule drugs, and personalized medicines, offering improved efficacy and reduced side effects.

Recent Key Developments of USA and Japan:

USA:

Approval of Datopotamab deruxtecan (Datroway): The FDA granted accelerated approval to Datroway on June 23, 2025, for certain patients with advanced or metastatic EGFR-mutated non-small cell lung cancer who have previously received other treatments.

Approval of Zongertinib (Hernexeos): On August 8, 2025, the FDA gave accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer with specific HER2 mutations.

Japan:

Sarclisa approval: In Japan, Sarclisa was approved on February 25, 2025, in combination with other drugs for the treatment of newly diagnosed multiple myeloma.

PMDA's new US office and consultation services: In March 2025, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) began offering consultation services from its new office in Washington, D.C., to help drug developers with the approval process in Japan.

Market Key Players:

F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
AstraZeneca.
Eisai Inc.
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company.
Incyte.
Eli Lilly and Company
Exelixis, Inc.

Growth Forecast Projected:

The Global Targeted Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Targeted Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=targeted-therapy-market

Market Segmentation:

By Type: Monoclonal Antibodies, Small Molecules, Others.

By Indication: Leukemia, Breast Cancer, Lung Cancer, GI Cancers, Melanoma, Others.

By Route of Administration: Oral, Parenteral.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/targeted-therapy-market

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

➠ How big is the Targeted Therapy market?

➠ Who are the key players in the Targeted Therapy market?

➠ What is the projected growth rate of the Targeted Therapy market?

➠ What is the market forecast for the Targeted Therapy industry by 2033?

➠ Which region is estimated to dominate the Targeted Therapy market through the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.